Cover Image
市場調查報告書

Five Prime Therapeutics, Inc.- 產品平台檢討

Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 204914
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Five Prime Therapeutics, Inc.- 產品平台檢討 Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年10月14日 內容資訊: 英文 39 Pages
簡介

Five Prime Therapeutics, Inc.是臨床階段的生物科技企業,正致力於研發新型蛋白質治療和抗體治療藥。提供腫瘤學、免疫學、糖尿病及再生醫療相關藥物,特別緻力於開發癌症與發炎疾病之治療藥。該公司也擁有獨家的檢查方法。

本報告提供Five Prime Therapeutics, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Five Prime Therapeutics, Inc.的基本資料

  • Five Prime Therapeutics, Inc.概要
  • 主要資訊
  • 企業資料

Five Prime Therapeutics, Inc.: R&D概要

  • 主要的治療範圍

Five Prime Therapeutics, Inc.: 開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Five Prime Therapeutics, Inc.: 開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Five Prime Therapeutics, Inc.: 藥物簡介

  • FP-1039
  • FPA-008
  • FP-1069
  • FPA-144
  • Antibodies for Solid Tumors
  • Monoclonal Antibodies for Cancer
  • Proteins For Asthma and Chronic Obstructive Pulmonary Disease
  • Proteins for Central Nervous System Disorders
  • Proteins for Fibrosis Related Inflammatory Diseases

Five Prime Therapeutics, Inc.: 開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Five Prime Therapeutics, Inc.: 最近的開發平台趨勢

Five Prime Therapeutics, Inc.: 暫停中的計劃

Five Prime Therapeutics, Inc.: 總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07650CDB

Summary

Global Markets Direct's, 'Five Prime Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Five Prime Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Five Prime Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Five Prime Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Five Prime Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Five Prime Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Five Prime Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Five Prime Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Five Prime Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Five Prime Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Five Prime Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Five Prime Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Five Prime Therapeutics, Inc. Snapshot
    • Five Prime Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Five Prime Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Five Prime Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Five Prime Therapeutics, Inc. - Pipeline Products Glance
    • Five Prime Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Five Prime Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Five Prime Therapeutics, Inc. - Drug Profiles
    • FPA-008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FP-1039
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FPA-144
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INBRX-110
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Proteins for Asthma and Chronic Obstructive Pulmonary Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Proteins for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Five Prime Therapeutics, Inc. - Pipeline Analysis
    • Five Prime Therapeutics, Inc. - Pipeline Products by Target
    • Five Prime Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Five Prime Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Five Prime Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Five Prime Therapeutics, Inc. - Recent Pipeline Updates
  • Five Prime Therapeutics, Inc. - Dormant Projects
  • Five Prime Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Five Prime Therapeutics, Inc., Key Information
  • Five Prime Therapeutics, Inc., Key Facts
  • Five Prime Therapeutics, Inc. - Pipeline by Indication, 2015
  • Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Five Prime Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Five Prime Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Five Prime Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2015
  • Five Prime Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Five Prime Therapeutics, Inc. - Phase I, 2015
  • Five Prime Therapeutics, Inc. - Preclinical, 2015
  • Five Prime Therapeutics, Inc. - Discovery, 2015
  • Five Prime Therapeutics, Inc. - Pipeline by Target, 2015
  • Five Prime Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Five Prime Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Five Prime Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Five Prime Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Five Prime Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Five Prime Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Five Prime Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Five Prime Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Five Prime Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Five Prime Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Five Prime Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Five Prime Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top